all-trans-retinoic acid, chemotherapy, and As 2 O 3 : an experience of 120 patients at a single institution. Int J Hematol 1999; 70: 248-260 The typical cytogenetic abnormality in APL is characterized by a specific chromosome translocation between the long arm of chromosome 15 and 17, t(15:17), that involves the fusion of the retinoic acid receptor-a (RAR-a) gene on chromosome 17 with the putative transcription factor PML on chromosome 15. The result is a hybrid PML-RAR-a gene, which is easily identified by the reverse transcriptase-polymerase chain reaction (RT-PCR). On cytogenetic examination, the presence of the t(15;17) is pathognomonic for APL and is highly correlated with a positive response to all-trans retinoic acid. It is highly rare for APL to be complicated by extramedullary disease (EMD) or recurrence. The latter usually affect the skin or the central nervous system, but may also on occasion involve the ear, the lung and mediastinum, the gums, the thymus, the breast, the testicles and the optic nerve.
Acute promyelocytic leukemia and aural recurrence: the importance of otoscopy in early diagnosis Leukemia (2003 Leukemia ( ) 17, 1418 Leukemia ( -1419 Leukemia ( . doi:10.1038 TO THE EDITOR Acute promyelocytic leukemia (APL) (type M3 FAB) is a relatively rare pathology that represents approximately 10% of all the acute forms of myeloblastic leukemia. It is most important to identify this particular subtype of leukemia because of its potential to cause lifethreatening disseminated intravascular coagulation and the clinical response to all-trans retinoic acid treatment limited to this form of leukemia.
The typical cytogenetic abnormality in APL is characterized by a specific chromosome translocation between the long arm of chromosome 15 and 17, t(15:17) , that involves the fusion of the retinoic acid receptor-a (RAR-a) gene on chromosome 17 with the putative transcription factor PML on chromosome 15. The result is a hybrid PML-RAR-a gene, which is easily identified by the reverse transcriptase-polymerase chain reaction (RT-PCR). On cytogenetic examination, the presence of the t(15;17) is pathognomonic for APL and is highly correlated with a positive response to all-trans retinoic acid. It is highly rare for APL to be complicated by extramedullary disease (EMD) or recurrence. The latter usually affect the skin or the central nervous system, but may also on occasion involve the ear, the lung and mediastinum, the gums, the thymus, the breast, the testicles and the optic nerve.
1,2
We present a case of APL relapse revealed by a earache and hearing loss as a result of leukemic infiltration of the external auditory canal (EAC). A 22-year-old female was referred to our department complaining of a headache that had persisted for 2 days, severe earache and sudden loss of hearing in the left ear. She has been treated successfully 2 years earlier for APL that had receded into dermatologic and medullary remission. She did not complain of sore throat, fever, cold, cough and/or other disturbances of the upper airways. Otomicroscopy was performed revealing the auditory canal to be edematous with an irregular reddish mass on the upper posterior external wall. The results of the blood tests showed mild leukocytosis, a high erythrocyte sedimentation rate (86 mm/h) and an increase in the alfa 1 and alfa 2 globulin value. Amoxycilline plus clavulanic acid were administrated intravenously for 5 days with the result that the earache disappeared, but the state of the auditory mass remained practically unchanged. Although the hematological tests with bone marrow aspiration and lumbar puncture resulted negative, the molecular biological analyses indicated a relapse of leukemia (transformation from negative to positive PCR for PML-RAR alfa). Biopsy of the EAC was carried out and the histopathological tests confirmed the suspected diagnosis of recurrence of APL. The patient was then transferred to the hematology department for the appropriate treatment.
Only 16 cases (including ours) of otological extramedullary APL exist in the literature, 10 involving the EAC (two of which bilaterally) and six involving the mastoid.
1,4-6 Breccia et al 5 explain ear involvement by the presence of bone marrow in the mastoid and leukemic cells spreading to the auditory canal.
5 This hypothesis is suggestive, nevertheless it does not explain the cases in which relapse is primarily localized in the EAC.
Of the otological relapses reported in the literature, 65% involve the EAC, 1,4-6 and in these cases it would seem more reasonable in our opinion to attribute the site of origin to the skin rather than the mastoid. It is a common knowledge that the site most frequently affected by EMD at relapse is the skin, being involved in half of the reported cases; 3 therefore, we are of the opinion that the previous conclusion does not apply when the EAC is involved.
The cases of contemporary involvement of the mastoid and the EAC are more complex and less easily interpreted. In our case, the first site of disease was the EAC with spreading in the middle ear and the epitympanum. We are led to believe that ear relapse is not due to marrow involvement, but to a neighboring invasion originating in the cutaneous structure of the EAC. This site is presumably in line with the tendency of APL to involve the skin, which Sanz et al 3 has hypothesized to occur at the site of vascular disruption accompained by secondary bleeding that is not, however, related to the hemorrhagic properties of the disease. In view of this Sanz et al 3 strongly recommend a thorough follow-up period with timely cutaneous biopsies and hematological tests in case of doubt. It should be remembered that otological recurrence of APL often occurs late and/or casually; therefore, it follows that patients with leukemia in remission must necessarily undergo time regular otoscopy. This examination is straightforward and easily performed, not being invasive and on its own may indicate a suspected diagnosis, thus proving to be of crucial importance in early diagnosis.
Four different clinical patterns may emerge from the otoscopic results, which we believe give indications as to the procedure of diagnosis to be followed.
(1) Isolated involvement of the EAC: Aural biopsy and histological examination in order to establish the nature of the tumor.
(2) Perforated eardrum with aural secretion: A straightforward cytological examination of the aural secretion can resolve any doubts on the diagnosis as suggested by Kikuno et al. 
TO THE EDITOR
Polycythaemia vera (PV) is a clonal haematological neoplasm characterised by excessive proliferation of the erythroid lineage. A number of recurring chromosomal abnormalities are seen in PV, including in order of frequency del(20q), +8, +9, del(7), del(5), and del(13q) as well as trisomy 1q. The del(20)(q?) is the most common and can be seen in approximately 10-15% of PV cases at diagnosis. The common deleted region (CDR) on 20q in myeloproliferative disorders (MPD) is well characterised and has been refined to a 2.7 Mb region spanning from D20S108 to D20S481. 1 Over 75% of the PV patients have no detectable chromosome abnormalities. A normal karyotype by G-banding analysis does not exclude occult rearrangements. This has been exemplified in cases of mental retardation 2 and acute leukaemia 3 where FISH and/or colour karyotyping identified submicroscopic rearrangements in cells with normal conventional karyotype. We have previously used microsatellite PCR to screen DNA from PV patients with a normal karyotype, and did not reveal any submicroscopic deletions. 4 These data indicated that the presence of genetically abnormal cell clone(s) within the bone marrow (BM) population, which were missed by the chromosome analysis, is highly improbable. Therefore, detection of a small deletion would greatly facilitate the identification of a potential target gene within the CDR. A range of FISH methods were used to study chromosome preparations of BM samples from 14 PV patients with apparently normal karyotype by G banding. All samples were obtained at the time of the diagnosis, which met the criteria of PV 5 and prior to any treatment.
Screening for cryptic rearrangements by FISH mapping
Possible candidate genes in the 20q CDR have been identified and prioritised according to their expression in CD34-positive cells.
3 For this study, PACS were selected to contain sequences from one or more of the potential candidate genes. The selection was therefore biased to gene-rich areas in the chromosome light bands on 20q. In all, 12 PACS, which spanned the MPD CDR on 20q11.2/q13.1, were hybridised to BM chromosomes preparations in pools of three probes labelled in three colours (Figure 1a) . Chromosome preparations from the cell line MHB14 with known del(20)(q11.2q13.1) were used as positive control. In all, 10-31 cells were analysed for each hybridisation experiment. Two hybridisation signals were obtained with each of the PAC probes on all 14 patient samples analysed (Figure 1a and b) . In each metaphase cell, six hybridisation signals were seen indicating no loss. In all MH1B14 cells, one hybridisation signal was obtained for each PAC probe from the CDR -a result consistent with the presence of a deletion in one of the chromosome 20 homologues (results not shown).
M-FISH and bands-specific painting analysis
Colour karyotyping was conducted on BM chromosome suspensions from three PV patients. In each case, 30 cells were captured and analysed to increase the chances of identifying an aberrant clone present at a low level. No cryptic structural chromosome rearrangements were detected in any of the metaphase cells even when highresolution mitotic figures were analysed (Figure 1c and d) . Simultaneous hybridisation of a whole chromosome 20 paint (WCP) and a 20q telomere probe established in all 14 cases that both chromosome 20 homologues were not involved in cryptic translocations (Figure 1e ). BSP for 20q11 and q13 regions were applied together to search for intrachromosomal rearrangements, which could have been missed by 24 colour karyotyping and WCP. Unequivocal interpretation of the BSP signals was only possible of mitotic figures with longer chromosomes (400 banding stage or above) obtained in 9/ 14 patients. Neither inv(20)(p11q13) as described in AML/MDS cases (6) nor any other aberrations were found (Figure 1f ).
